Oncolytics Biotech Inc ONCY
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ONCY is a good fit for your portfolio.
News
-
Oncolytics Announces the Anal Cancer Cohort of the GOBLET Phase 1/2 Study of Pelareorep and Atezolizumab Has Met the Success Criteria for Efficacy
-
Oncolytics Provides Update on Pancreatic Cancer Program for Pelareorep
-
Oncolytics Biotech® and SOLTI Present Further Positive Pelareorep Translational Data at SITC
-
Oncolytics Biotech® Reports Third Quarter 2023 Financial Results and Operational Highlights
-
Oncolytics Presents Positive Updated Pancreatic Cancer Data from GOBLET Phase 1/2 Study at ESMO
-
Oncolytics Achieves Success Criteria for Efficacy in the Third-Line Colorectal Cancer Cohort of the GOBLET Study
-
Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights
-
Oncolytics Biotech® To Present Two Posters on the Pelareorep-Based GOBLET Study at ESMO 2023
Trading Information
- Previous Close Price
- $1.45
- Day Range
- $1.39–1.45
- 52-Week Range
- $1.09–3.39
- Bid/Ask
- $1.40 / $1.55
- Market Cap
- $104.23 Mil
- Volume/Avg
- 557,032 / 415,045
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Oncolytics Biotech Inc is a development-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. Its clinical development plan has the approval of its products as quickly as possible and expands its products into commercially valuable new treatment areas as objectives. The primary focus is to advance programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 29
Valuation
|
Metric
|
ONCY
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 4.88 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ONCY
|
|---|---|
Quick Ratio | 4.05 |
Current Ratio | 4.53 |
Interest Coverage | — |
Quick Ratio
ONCY
Profitability
|
Metric
|
ONCY
|
|---|---|
Return on Assets (Normalized) | −81.98% |
Return on Equity (Normalized) | −117.88% |
Return on Invested Capital (Normalized) | −118.94% |
Return on Assets
ONCY
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Bqtt | $458.6 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Vjfhgq | $90.5 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Sknljm | $88.8 Bil | |
SGEN
| Seagen Inc Ordinary Shares | Rltzh | $40.1 Bil | |
MRNA
| Moderna Inc | Gdmqs | $30.4 Bil | |
ARGX
| argenx SE ADR | Yjvfk | $27.0 Bil | |
BNTX
| BioNTech SE ADR | Mcy | $23.6 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Ftspxls | $21.5 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Gdcdgj | $17.4 Bil | |
INCY
| Incyte Corp | Kkjjd | $12.1 Bil |